In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae | Zendy

Bartolomé Moyá | Zendy; Isabel M. Barceló | Zendy; Gabriel Cabot | Zendy; Gabriel Torrens | Zendy; Snehal Palwe | Zendy; Prashant Joshi | Zendy; Kushal Umarkar | Zendy; Swapna Takalkar | Zendy; Hariharan Periasamy | Zendy; Sachin Bhagwat | Zendy; Mahesh Patel | Zendy; Germán Bou | Zendy; Antonio Oliver | Zendy

Open Access

In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae

Author(s) -

Bartolomé Moyá,

Isabel M. Barceló,

Gabriel Cabot,

Gabriel Torrens,

Snehal Palwe,

Prashant Joshi,

Kushal Umarkar,

Swapna Takalkar,

Hariharan Periasamy,

Sachin Bhagwat,

Mahesh Patel,

Germán Bou,

Antonio Oliver

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00128-19

Subject(s) - aztreonam , cefepime , klebsiella pneumoniae , acinetobacter baumannii , microbiology and biotechnology , in vivo , pseudomonas aeruginosa , biology , antibiotics , escherichia coli , imipenem , bacteria , biochemistry , antibiotic resistance , genetics , gene

Zidebactam and WCK 5153 are novel bicyclo-acyl hydrazide (BCH) agents that have previously been shown to act as β-lactam enhancer (BLE) antibiotics inPseudomonas aeruginosa andAcinetobacter baumannii . The objectives of this work were to identify the molecular targets of these BCHs inKlebsiella pneumoniae and to investigate their potential BLE activity for cefepime and aztreonam against metallo-β-lactamase (MBL)-producing strainsin vitro andin vivo .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research